Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
SUMMARY Sterile inflammation after tissue damage is a ubiquitous response, and yet has the highest amplitude in the liver. This has major clinical consequences with alcoholic and non-alcoholic steatohepatitis (ASH and NASH) accounting for the majority of liver disease in industrialized countries, and both lacking therapy. Requirements for sustained sterile inflammation include increased oxidative stress, and activation of the HIF-1α signaling pathway. We demonstrate the ability of digoxin, a cardiac glycoside, to protect from liver inflammation and damage in ASH and NASH. Digoxin was effective in maintaining cellular redox homeostasis, and suppressing HIF-1α pathway activation. A proteomic screen revealed that digoxin binds pyruvate kinase M2 (PKM2), and independent of PKM2 kinase activity results in chromatin remodeling and down-regulation of HIF-1α transactivation. These data identify PKM2 as a mediator and therapeutic target for regulating liver sterile inflammation, and demonstrate a novel role for digoxin which can effectively protect the liver from ASH and NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 1×
“PKM2 is the key metabolic regulator present predominantly in activated myeloid cells (Christofk et al., 2008; Palsson-McDermott et al., 2015; Tamada et al., 2012) and exists primarily as an enzymatically inactive monomer or dimer.”
BackgroundNonalcoholic Fatty Liver Disease
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., McCullough, A. J., Natale, S., Forlani, G., & Melchionda, N. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1844 · Cited by 2,581 · cited 1×
“This is seen in experimental models including acetaminophen toxicity, alcoholic steatohepatitis (ASH), and metabolic syndrome-associated development of non-alcoholic steatohepatitis (NASH) (Kubes and Mehal, 2012; Marchesini et al., 2001).”
BackgroundHypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 2×
“…regulator of homeostatic responses to hypoxia and oxidative stresses by activating transcriptional events important for driving inflammation, metabolism, and cell survival (Arteel et al., 1997; Ju et al., 2016; Lee et al., 2014; Majmundar et al., 2010; Nath et al., 2011; Palmer and Clegg, 2014).”
BackgroundPalsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A. R., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. M., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G. W., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.005 · Cited by 1,397
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032 · cited 1×
“Several cellular mechanisms contribute to the production of reactive oxygen species (ROS) in the liver; increased leakage of protons across the inner mitochondrial membrane is an important one (Koliaki et al., 2015).”
BackgroundPyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816 · cited 1×
“The small molecule TEPP-46 stabilizes the tetrameric form of PKM2 and reduces PKM2 nuclear translocation and transcription (Anastasiou et al., 2012; Palsson-McDermott et al., 2015).”
BackgroundSterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · cited 3×
“This is seen in experimental models including acetaminophen toxicity, alcoholic steatohepatitis (ASH), and metabolic syndrome-associated development of non-alcoholic steatohepatitis (NASH) (Kubes and Mehal, 2012; Marchesini et al., 2001).”
BackgroundSelf-citationDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 3×
“These mechanistic insights into the role of the HIF-1a pathway in sterile inflammation may have great clinical relevance due to the ability of cardiac glycosides (CGs) to inhibit HIF-1a activation (Zhang et al., 2008).”
BackgroundLee, Y. S., Kim, J.-W., Osborne, O., Oh, D. Y., Sasik, R., Schenk, S., Chen, A., Chung, H., Murphy, A., Watkins, S. M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.012 · Cited by 598
Digitalis: Mechanisms of Action and Clinical Use
Epstein, F. H., & Smith, T. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802113180606 · Cited by 346 · cited 1×
“CGs are well known in cardiology due to their effects of increasing ionotropy, and decreasing chronotropy, via partial inhibition of the Na+/K+ ATPase on the plasma membrane of myocytes (Smith, 1988).”
High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo
Mantena, S. K., Vaughn, D. P., Andringa, K. K., Eccleston, H. B., King, A. L., Abrams, G. A., Doeller, J. E., Kraus, D. W., Darley-Usmar, V. M., & Bailey, S. M. (2009) · Biochemical Journal · doi:10.1042/bj20080868 · Cited by 265 · cited 10×
“These features generate the possibility of HIF-1a pathway inhibition by digoxin as a therapeutic option for ASH and NASH.”
BackgroundInfluential
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Di Francesco, A., Di Germanio, C., Bernier, M., & de Cabo, R. (2018) · Science · doi:10.1126/science.aau2095 · Cited by 497
Ketogenic diet in the treatment of cancer – Where do we stand?
Weber, D. D., Aminzadeh-Gohari, S., Tulipan, J., Catalano, L., Feichtinger, R. G., & Kofler, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.026 · Cited by 464
The role of hypoxia-inducible factors in metabolic diseases
Gonzalez, F. J., Xie, C., & Jiang, C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0096-z · Cited by 407
Macrophages in metabolic associated fatty liver disease
Alharthi, J., Latchoumanin, O., George, J., & Eslam, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i16.1861 · Cited by 65
Metadata
- Authors
- Ouyang, X., Han, S.-N., Zhang, J.-Y., Dioletis, E., Nemeth, B. T., Pacher, P., Feng, D., Bataller, R., Cabezas, J., Stärkel, P., Caballeria, J., Pongratz, R. L., Cai, S.-Y., Schnabl, B., Hoque, R., Chen, Y., Yang, W.-H., Garcia-Martinez, I., Wang, F.-S., Gao, B., Torok, N. J., Kibbey, R. G., & Mehal, W. Z.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 27
- Issue
- 2
- Pages
- 339-350.e3
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W2785692436
- Cited by
- 115
- References
- 11
- FWCI
- 6.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.